Skip to main content
. 2014 Jan;85(1):91–104. doi: 10.1124/mol.113.089482

Fig. 4.

Fig. 4.

DMR studies indicate that ligand effects in HT-29 cells are mediated via GPR35. (A) The capacity of varying concentrations of lodoxamide (●), bufrolin (□), zaprinast (♦), and cromolyn disodium (○) to modulate DMR signals in HT-29 cells is shown. (B) Effects of defined concentrations of the human GPR35-specific antagonist ML-145 on the agonist effects of lodoxamide are shown.